<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The FHIT gene, which spans the common fragile site FRA3B, has been shown to produce aberrant transcripts in a variety of <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> types </plain></SENT>
<SENT sid="1" pm="."><plain>Homozygous deletions within the FHIT locus have been detected only in <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e>-derived cell lines and LOH has been described in numerous <z:e sem="disease" ids="C0677930" disease_type="Neoplastic Process" abbrv="">primary tumors</z:e> </plain></SENT>
<SENT sid="2" pm="."><plain>Based on these findings and its location on 3p, FHIT has been proposed as a <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> suppressor gene </plain></SENT>
<SENT sid="3" pm="."><plain>To further study the relationship of FRA3B to the findings regarding the FHIT gene and to determine the extent of FHIT <z:chebi fb="2" ids="33699">mRNA</z:chebi> alterations in early stages of <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> development, the status of the FHIT gene was evaluated in the <z:e sem="disease" ids="C0032927" disease_type="Neoplastic Process" abbrv="">premalignant condition</z:e> of <z:hpo ids='HP_0100580'>Barrett's esophagus</z:hpo> and associated esophageal <z:mp ids='MP_0009308'>adenocarcinomas</z:mp> </plain></SENT>
<SENT sid="4" pm="."><plain>FHIT expression was investigated by RT-PCR in <z:mpath ids='MPATH_458'>normal</z:mpath> esophageal, Barrett's <z:mpath ids='MPATH_160'>metaplasia</z:mpath> and <z:mp ids='MP_0009308'>adenocarcinoma</z:mp> tissues from 15 patients </plain></SENT>
<SENT sid="5" pm="."><plain>Alterations of FHIT transcripts were observed in 12/14 (86%) of Barrett's <z:mpath ids='MPATH_160'>metaplasia</z:mpath> and in 14/15 (93%) of the <z:mp ids='MP_0009308'>adenocarcinomas</z:mp> from the same patients </plain></SENT>
<SENT sid="6" pm="."><plain>Characterization of the altered transcripts revealed FHIT <z:chebi fb="2" ids="33699">mRNA</z:chebi> lacking one or more exons, with deletion of exons 5-7 being most frequent </plain></SENT>
<SENT sid="7" pm="."><plain>Analysis of genomic DNA from 20 patients showed homozygous deletions involving exon 5 of FHIT in 4/20 (20%) esophageal <z:mp ids='MP_0009308'>adenocarcinomas</z:mp>, and 7/20 (35%) <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> demonstrated hemizygous loss </plain></SENT>
<SENT sid="8" pm="."><plain>Genomic deletions also involved the BE758-6 locus, indicating that a large region is deleted </plain></SENT>
<SENT sid="9" pm="."><plain>Fluorescence in situ hybridization (FISH) analysis demonstrated that this region of deletion is localized within FRA3B </plain></SENT>
<SENT sid="10" pm="."><plain>Our results extend the range of <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> types in which altered FHIT transcripts have been demonstrated and show that these alterations can be seen in the premalignant stage of <z:e sem="disease" ids="C0014859" disease_type="Neoplastic Process" abbrv="">esophageal tumor</z:e> development </plain></SENT>
<SENT sid="11" pm="."><plain>These results indicate that the fragility and recombination-prone nature of FRA3B is related to <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e>-specific <z:mp ids='MP_0008866'>chromosomal instability</z:mp> affecting the FHIT gene in esophageal <z:mp ids='MP_0009308'>adenocarcinoma</z:mp> development </plain></SENT>
</text></document>